ATE497492T1 - Reinigung von montelukast - Google Patents

Reinigung von montelukast

Info

Publication number
ATE497492T1
ATE497492T1 AT06786369T AT06786369T ATE497492T1 AT E497492 T1 ATE497492 T1 AT E497492T1 AT 06786369 T AT06786369 T AT 06786369T AT 06786369 T AT06786369 T AT 06786369T AT E497492 T1 ATE497492 T1 AT E497492T1
Authority
AT
Austria
Prior art keywords
montelukast
cleaning
impurity
isolation
provides methods
Prior art date
Application number
AT06786369T
Other languages
English (en)
Inventor
Greta Sterimbaum
Evgeny Shapiro
Kobi Chen
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE497492T1 publication Critical patent/ATE497492T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Quinoline Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06786369T 2005-07-05 2006-07-05 Reinigung von montelukast ATE497492T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69700005P 2005-07-05 2005-07-05
PCT/US2006/026192 WO2007005965A1 (en) 2005-07-05 2006-07-05 Purification of montelukast

Publications (1)

Publication Number Publication Date
ATE497492T1 true ATE497492T1 (de) 2011-02-15

Family

ID=37076280

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06786369T ATE497492T1 (de) 2005-07-05 2006-07-05 Reinigung von montelukast

Country Status (11)

Country Link
US (2) US7812168B2 (de)
EP (1) EP1904448B1 (de)
JP (1) JP2008510840A (de)
KR (2) KR20090015186A (de)
CN (1) CN101213177A (de)
AT (1) ATE497492T1 (de)
CA (1) CA2608369A1 (de)
DE (1) DE602006019964D1 (de)
ES (1) ES2358923T3 (de)
IL (1) IL185731A0 (de)
WO (1) WO2007005965A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7547787B2 (en) 2004-04-21 2009-06-16 Teva Pharmaceutical Industries Ltd. Processes for preparing montelukast sodium
US20070161796A1 (en) * 2005-11-16 2007-07-12 Ilan Kor-Sade Drying methods of montelukast sodium by azeotropic removal of the solvent
ES2403067T3 (es) * 2005-12-13 2013-05-13 Msn Laboratories Limited Un procedimiento mejorado para la preparación de montelukast y sus sales farmaceúticamente aceptables
EP1886998A1 (de) 2006-08-09 2008-02-13 Esteve Quimica, S.A. Verfahren zur Reinigung von Montelukast und dessen Aminesalzen
US8115004B2 (en) * 2006-11-20 2012-02-14 Msn Laboratories Limited Process for pure montelukast sodium through pure intermediates as well as amine salts
US20080188664A1 (en) * 2007-01-15 2008-08-07 Chemagis Ltd. Process for preparing montelukast sodium containing controlled levels of impurities
PL205444B1 (pl) * 2007-05-02 2010-04-30 Zak & Lstrok Ady Farmaceutyczn Sposób wytwarzania soli sodowej kwasu 1-(((1(R)-(3-(2-(7--chloro-2- chinolinylo)-etenylo)fenylo)-3-(2-(1-hydroksy-1- metyloetylo)fenylo)propylo)sulfanylo)metylo)-cyklopropanooctowego
CZ302518B6 (cs) * 2007-07-09 2011-06-29 Zentiva, A. S. Zpusob izolace a cištení montelukastu
WO2009027990A1 (en) * 2007-08-29 2009-03-05 Morepen Laboratories Limited Salts of montelukast and process therefor
WO2009117381A2 (en) * 2008-03-17 2009-09-24 Dr. Reddy's Laboratories Ltd. Preparation of montelukast and its salts
ES2605473T3 (es) * 2008-05-26 2017-03-14 Laurus Labs Private Limited Un procedimiento mejorado para la preparación de Montelukast y sus sales
EP2287154A1 (de) 2009-07-14 2011-02-23 KRKA, D.D., Novo Mesto Effiziente Synthese zur Herstellung von Montelukast
US8546573B2 (en) * 2009-11-18 2013-10-01 Cadila Healthcare Limited Process for the preparation of 7-ethyl-10-[4-(1-piperidino)-1-piperdino] carbonyloxy-camptothecin hydrochloride trihydrate
EP2552892A1 (de) 2010-03-31 2013-02-06 KRKA, D.D., Novo Mesto Effiziente synthese zur herstellung von montelukast und neue kristalline form von zwischenprodukten darin
KR100990046B1 (ko) * 2010-07-30 2010-10-26 동국제약 주식회사 신규한 몬테루카스트 4-할로 벤질아민염 및 이를 이용한 몬테루카스트 나트륨염의 제조방법
JP2015010049A (ja) * 2013-06-27 2015-01-19 株式会社トクヤマ モンテルカストアルキルエステルを製造する方法
CN103570618A (zh) * 2013-09-30 2014-02-12 浙江车头制药股份有限公司 一种孟鲁司特钠盐的制备方法
CN103570619B (zh) * 2013-11-08 2015-12-09 南京靖龙药物研发有限公司 一种孟鲁司特钠衍生物的制备方法
CN103772275B (zh) * 2013-12-30 2015-10-28 浙江车头制药股份有限公司 孟鲁司特二正丙胺盐晶型及制备方法和应用
WO2015163978A1 (en) * 2014-04-25 2015-10-29 R.P. Scherer Technologies, Llc A stable montelukast solution
CN104119270A (zh) * 2014-08-12 2014-10-29 牡丹江恒远药业有限公司 一种孟鲁司特钠的制备方法
CN105585524B (zh) * 2016-02-29 2018-03-02 山东新时代药业有限公司 一种由孟鲁司特酸制备孟鲁司特钠的方法
CN105924392B (zh) * 2016-02-29 2018-03-02 山东新时代药业有限公司 一种孟鲁司特钠制备方法
CN107049940A (zh) * 2017-03-10 2017-08-18 重庆西南医院 一种促进孟鲁司特钠经直肠吸收的促进剂及其使用方法
CN108125908A (zh) * 2017-12-14 2018-06-08 重庆西南医院 一种孟鲁司特钠鼻用溶液及其制备方法
CN110045049B (zh) * 2018-01-17 2021-07-09 天津药物研究院有限公司 一种同时测定孟鲁司特钠及其制剂多种有关物质的方法
EP3846792A4 (de) 2018-09-06 2022-10-12 Innopharmascreen Inc. Verfahren und zusammensetzungen zur behandlung von asthma oder morbus parkinson

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851409A (en) * 1986-02-14 1989-07-25 Merck Frosst Canada Inc. 2-substituted quinoline dioic acids and pharmaceutical compositions
DE3611108C1 (de) 1986-04-03 1987-07-30 Balcke Duerr Ag Verfahren und Vorrichtung zur druckdichten Befestigung von geraden Rohren zwischen zwei Rohrscheiben
US5565473A (en) * 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
EP0480716A1 (de) * 1990-10-12 1992-04-15 Merck Frosst Canada Inc. Gesättigte Hydroxyalkylchinolinsäuren zur Verwendung als Leukotrien-Antagonisten
US5266568A (en) * 1990-10-12 1993-11-30 Merck Frosst Canada, Inc. Hydroxyalkylquinoline ether acids as leukotriene antagonists
US5856322A (en) * 1990-10-12 1999-01-05 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
DK0480717T3 (da) 1990-10-12 1999-02-08 Merck Frosst Canada Inc Umættede hydroxyalkylquinolinsyrer som leukotrienantagonister
IE920499A1 (en) 1991-02-21 1992-08-26 Merck Frosst Canada Inc Quinoline-containing ketoacids as leukotriene antagonists
US5506227A (en) * 1992-04-13 1996-04-09 Merck Frosst Canada, Inc. Pyridine-substituted benzyl alcohols as leukotriene antagonists
TW448160B (en) 1993-12-28 2001-08-01 Merck & Co Inc Novel dicyclohexylamine salt and process for the preparation of leukotriene antagonists
FI946209A0 (fi) 1994-12-30 1994-12-30 Nokia Telecommunications Oy Foerfarande foer jaemfoerande av attributvaerden hos kontrollerbara objektuttryck i ett naetelement
US5523477A (en) * 1995-01-23 1996-06-04 Merck & Co., Inc. Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid
US5869673A (en) * 1997-02-28 1999-02-09 Merck & Co., Inc. Process for 3-(2-(7-chloro-2-quinolinyl)ethenyl) - benzaldehyde
US5952347A (en) * 1997-03-13 1999-09-14 Merck & Co., Inc. Quinoline leukotriene antagonists
GB9812413D0 (en) * 1998-06-10 1998-08-05 Glaxo Group Ltd Compound and its use
FI104718B (fi) 1998-06-18 2000-03-31 Orion Yhtymae Oyj [[4-(2-atsido-3-metyyli-5-oksotetrahydrofuran-2-yyli)fenyyli]hydratsono]propaanidinitriili käytettäväksi referenssiaineena levosimendaanierien analyysissä
CN1420113A (zh) 2001-11-16 2003-05-28 北京上地新世纪生物医药研究所 孟鲁司特钠的制备方法及其制备中间体
CN1171873C (zh) 2001-12-26 2004-10-20 北京上地新世纪生物医药研究所 一种孟鲁司特钠的制备方法及其制备中间体
WO2003066598A1 (en) 2002-02-07 2003-08-14 Dr. Reddy's Laboratories Ltd. Novel anhydrous amorphous forms of montelukast sodium salt
US20050107612A1 (en) * 2002-12-30 2005-05-19 Dr. Reddy's Laboratories Limited Process for preparation of montelukast and its salts
JP2006523699A (ja) 2003-04-15 2006-10-19 メルク　エンド　カムパニー　インコーポレーテッド モンテルカストナトリウムの多形形態
EP1631550B1 (de) * 2003-06-06 2012-01-11 Morepen Laboratories Ltd. Verbessertes verfahren zur herstellung von montelukastsäure natriumsalz in amorpher form
US7553853B2 (en) 2003-10-10 2009-06-30 Synthon Bv Solid-state montelukast
US7482460B2 (en) * 2003-12-10 2009-01-27 Hypnion, Inc. Doxepin analogs and methods of use thereof
US20070225325A1 (en) 2004-01-28 2007-09-27 Pliva-Istrazivanje I Razvoj D.O.O. Solid Forms of Montelukast Acid
WO2005075427A2 (en) 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast sodium polymorphs
KR20060117356A (ko) * 2004-01-30 2006-11-16 테바 파마슈티컬 인더스트리즈 리미티드 몬테루카스트 유리산 다형체
WO2005074893A1 (en) 2004-02-03 2005-08-18 Chemagis Ltd. Stable amorphous forms of montelukast sodium
US7189853B2 (en) 2004-04-15 2007-03-13 Dr. Reddy's Laboratories Limited Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (Montelukast) and its pharmaceutically acceptable salts
US7547787B2 (en) * 2004-04-21 2009-06-16 Teva Pharmaceutical Industries Ltd. Processes for preparing montelukast sodium
US7829716B2 (en) 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor
US7501517B2 (en) 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor
CA2560984A1 (en) 2004-06-01 2005-12-15 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Process for preparation of amorphous form of a drug
US20090143590A1 (en) 2004-07-19 2009-06-04 Matrix Laboratories Ltd. Process for the Preparation of Montelukast and its Salts
WO2006021974A1 (en) 2004-08-23 2006-03-02 Morepen Laboratories Limited A process for synthesizing diol (viii)-an intermediate of montelukast sodium
PL205637B1 (pl) 2004-10-22 2010-05-31 Inst Farmaceutyczny Sposób wytwarzania kwasu (R,E)-(1-{1-{3-[2-(7-chlorochinolin-2-ylo)etenylo]fenylo}-3-[2-(1-hydroksy-1-metyloetylo)fenylo] propylosulfanylometylo}cyklopropylo)octowego i/lub jego farmaceutycznie dopuszczalnych soli
US20080146809A1 (en) * 2004-11-19 2008-06-19 Matrix Laboratories Ltd Process for the Preparation of Novel Amorphous Montelukast Sodium
US20080214822A1 (en) 2004-11-30 2008-09-04 Medichem, S.A. Process For the Preparation of a Leukotriene Antagonist
WO2006064269A2 (en) 2004-12-17 2006-06-22 Cipla Limited Salts of leukotriene antagonist montelukast
ITMI20050247A1 (it) 2005-02-18 2006-08-19 Chemi Spa Processo per la preparazione di montelukast
WO2007004237A2 (en) 2005-07-05 2007-01-11 Matrix Laboratories Ltd A process for the preparation of montelukast
WO2007012075A2 (en) 2005-07-20 2007-01-25 Dr. Reddy's Laboratories Ltd. Preparation of montelukast
EP1783117A1 (de) 2005-11-04 2007-05-09 Esteve Quimica, S.A. Verfahren zur Herstellung eines Leukotrienantagonisten und dessen Zwischenprodukte
US20070161796A1 (en) 2005-11-16 2007-07-12 Ilan Kor-Sade Drying methods of montelukast sodium by azeotropic removal of the solvent
AR057909A1 (es) 2005-11-18 2007-12-26 Synthon Bv Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
ES2403067T3 (es) 2005-12-13 2013-05-13 Msn Laboratories Limited Un procedimiento mejorado para la preparación de montelukast y sus sales farmaceúticamente aceptables
CA2632954A1 (en) 2005-12-23 2007-06-28 Glade Organics Private Limited An improved process for the manufacture of montelukast sodium
IL181485A0 (en) 2006-02-21 2007-07-04 Chemagis Ltd Processes for preparing novel montelukast salts
IL181607A0 (en) 2006-02-27 2007-07-04 Chemagis Ltd Novel process for preparing montelukast and salts thereof
WO2007101841A2 (en) 2006-03-06 2007-09-13 Farmaprojects, S. A. Process for preparing a leukotriene antagonist
EP1996552A1 (de) 2006-03-17 2008-12-03 Synthon B.V. Montelukast-amantadin-salz
CA2649189A1 (en) 2006-04-12 2007-10-18 Glade Organics Private Limited An improved process for the manufacture of montelukast sodium
US20060223999A1 (en) * 2006-05-10 2006-10-05 Chemagis Ltd. Process for preparing montelukast and precursors thereof
GB0614485D0 (en) 2006-07-21 2006-09-27 Pliva Istrazivanje I Razvoj D Process
EP2069307A4 (de) 2006-08-04 2010-03-03 Matrix Lab Ltd Verfahren zur herstellung von montelukast und salzen daraus
EP1886998A1 (de) 2006-08-09 2008-02-13 Esteve Quimica, S.A. Verfahren zur Reinigung von Montelukast und dessen Aminesalzen
EP1886997A1 (de) 2006-08-09 2008-02-13 Esteve Quimica, S.A. Verfahren zur Aufreinigung von Montelukast
WO2008023044A1 (en) 2006-08-23 2008-02-28 Sandoz Ag Process for the preparation of montelukast free acid and its amine salts
KR20090080038A (ko) 2006-09-15 2009-07-23 씨아이피엘에이 엘티디. 몬테루카스트의 제조방법 및 그의 중간체
WO2008035379A2 (en) 2006-09-19 2008-03-27 Aptuit Laurus Private Limited Process for and intermediates of leukotriene antagonists
GB0618703D0 (en) 2006-09-22 2006-11-01 Almac Sciences Ltd Synthesis of leikotriene compounds
US7700776B2 (en) * 2006-10-24 2010-04-20 Formosa Laboratories, Inc. Compounds and preparation for montelukast sodium
SI22382A (sl) 2006-10-26 2008-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Nov postopek za pripravo montelukasta
WO2008058118A2 (en) 2006-11-06 2008-05-15 Dr. Reddy's Labortories, Ltd. Preparation of montelukast and its salts
US8115004B2 (en) 2006-11-20 2012-02-14 Msn Laboratories Limited Process for pure montelukast sodium through pure intermediates as well as amine salts
KR100774088B1 (ko) 2006-12-14 2007-11-06 한미약품 주식회사 몬테루카스트의 제조방법 및 이에 사용되는 중간체
US7271268B1 (en) * 2006-12-22 2007-09-18 Formosa Laboratories Inc. Process for preparation of [1-(mercaptomethyl)cyclopropyl]acetic acid and related derivatives
CZ302238B6 (cs) 2007-01-09 2011-01-05 Zentiva, A. S. Zpusob prípravy montelukastu
US20080188664A1 (en) * 2007-01-15 2008-08-07 Chemagis Ltd. Process for preparing montelukast sodium containing controlled levels of impurities
EP1958936A1 (de) 2007-02-14 2008-08-20 Inke, S.A. Verfahren zur Gewinnung von Montelukast
WO2008126075A1 (en) 2007-04-12 2008-10-23 Chemagis Ltd. Process for preparing montelukast and salts thereof using optically impure 2-(2-(3(s)-(3-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-hydroxypropyl)phenyl-2-propanol
PL205444B1 (pl) 2007-05-02 2010-04-30 Zak & Lstrok Ady Farmaceutyczn Sposób wytwarzania soli sodowej kwasu 1-(((1(R)-(3-(2-(7--chloro-2- chinolinylo)-etenylo)fenylo)-3-(2-(1-hydroksy-1- metyloetylo)fenylo)propylo)sulfanylo)metylo)-cyklopropanooctowego
JP6546550B2 (ja) 2016-03-09 2019-07-17 日本特殊陶業株式会社 真空吸着部材および真空吸着方法

Also Published As

Publication number Publication date
CA2608369A1 (en) 2007-01-11
IL185731A0 (en) 2008-01-06
EP1904448B1 (de) 2011-02-02
JP2008510840A (ja) 2008-04-10
DE602006019964D1 (de) 2011-03-17
WO2007005965A1 (en) 2007-01-11
KR20090015186A (ko) 2009-02-11
KR100899585B1 (ko) 2009-05-27
EP1904448A1 (de) 2008-04-02
US20100076195A1 (en) 2010-03-25
KR20070088504A (ko) 2007-08-29
US20070078158A1 (en) 2007-04-05
CN101213177A (zh) 2008-07-02
US7812168B2 (en) 2010-10-12
ES2358923T3 (es) 2011-05-16

Similar Documents

Publication Publication Date Title
ATE497492T1 (de) Reinigung von montelukast
SE0301372D0 (sv) Novel compounds
TW200604184A (en) Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
MXPA05013553A (es) Pirrolodihidroisoquinolinas como inhibidores de pde10.
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
ATE427965T1 (de) Antikírper gegen 25-hydroxyvitamin d
EA201070247A1 (ru) Ингибиторы протеасом
CY1109998T1 (el) Ενδυναμωτες υποδοχεων γλουταμινικου
CL2008000069A1 (es) Metodo de preparacion de compuestos derivados de 3,4-dihidroquinolina.
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
WO2005108358A3 (en) Pyrrolidine derivatives useful as bace inhibitors
MX2010006738A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
MX2010006736A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
PT1633697E (pt) Processo para a produção de compostos substituídos de 3-arilbutilamina
BRPI0414599A (pt) pirrol-indóis substituìdos
TW200624426A (en) BACE inhibitors
IL176142A (en) Processes for preparing montelukast sodium
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
DK1519944T3 (da) Fremgangsmåder til fremstilling af fibrinogen
ATE446314T1 (de) Methode zur reinigung von fsh
TW200619206A (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
WO2006132739A3 (en) Novel chemical compounds
WO2006135938A3 (en) Fluorometric method for monitoring a clean-in-place system
ATE539085T1 (de) Verfahren zur isolierung von haptoglobin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties